Major investment in regenerative medicine enters its last stage — and the money might run out before treatments are ready

Quick Read

Deals continue to be signed for gene-editing tool called Crispr-Cas9

Quick Read

Vice president among speakers at dedication of $125 million Bloomberg-Kimmel Institute for Cancer Immunotherapy

Quick Read

Healthy Indiana pushes Medicaid’s traditional boundaries, which is why it has the attention of other conservative states. The plan demands something from all enrollees, even those below the poverty line. The poorest Hoosiers can get coverage with vision and even dental benefits, but only if they make small monthly contributions — ranging from $1 to $28 — to individual accounts similar to health savings accounts

Quick Read

One of the top providers of gene-sequencing technology, Illumina, is teaming up with investors in hopes of buttressing the growing universe of genetic analysis businesses

Quick Read

Editas Medicine, based in Cambridge, Mass., already had money. Founded in Nov 2013 with $43 million, it was the first big CRISPR effort out of the gate. But those investments are dwarfed by today’s announcement, which will put $120 million into the tiny company’s bank account – enough, Editas says, to keep it running for a projected three years

Quick Read

Drug companies are exploiting rare mutations that make one person nearly immune to pain, another to broken bones

Quick Read

Nigeria is on the verge of being polio-free. And that would mean that for the first time ever there’s no ongoing polio transmission on the African continent. Nigeria is one of just three countries in the world, along with Pakistan and Afghanistan, where polio transmission has never been fully stopped

Quick Read